Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.
BACKGROUND
Published economic assessments of rotavirus vaccination typically use modelling, mainly static Markov cohort models with birth cohorts followed up to the age of 5 years. Rotavirus vaccination has now been available for several years in some countries, and data have been collected to evaluate the real-world impact of vaccination on rotavirus hospitalisations. This study compared the economic impact of vaccination between model estimates and observed data on disease-specific hospitalisation reductions in a country for which both modelled and observed datasets exist (Belgium).


METHODS
A previously published Markov cohort model estimated the impact of rotavirus vaccination on the number of rotavirus hospitalisations in children aged <5 years in Belgium using vaccine efficacy data from clinical development trials. Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged <5 years between 1 June 2004 and 31 May 2006 (pre-vaccination study period) or 1 June 2007 to 31 May 2010 (post-vaccination study period) were analysed from nine hospitals in Belgium and compared with the modelled estimates.


RESULTS
The model predicted a smaller decrease in hospitalisations over time, mainly explained by two factors. First, the observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model included a 'waning' effect, i.e. reduced vaccine effectiveness over time. The observed data suggested this waning effect did not occur during that period, and so the model systematically underestimated vaccine effectiveness during the first 4 years after vaccine implementation.


CONCLUSIONS
Model predictions underestimated the direct medical economic value of rotavirus vaccination during the first 4 years of vaccination by approximately 10% when assessing hospitalisation rates as compared with observed data in Belgium.
Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium. baudouin.a.standaert@gsk.com
Baudouin
B
Standaert
Jorge A
JA
Gomez
Marc
M
Raes
Serge
S
Debrus
F Raúl
FR
Velázquez
Maarten J
MJ
Postma
D001530:Belgium; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015233:Models, Statistical; D012401:Rotavirus / Q000502:physiology*; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics / Q000706:statistics & numerical data*